AU2003247826B2 - Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins - Google Patents

Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins Download PDF

Info

Publication number
AU2003247826B2
AU2003247826B2 AU2003247826A AU2003247826A AU2003247826B2 AU 2003247826 B2 AU2003247826 B2 AU 2003247826B2 AU 2003247826 A AU2003247826 A AU 2003247826A AU 2003247826 A AU2003247826 A AU 2003247826A AU 2003247826 B2 AU2003247826 B2 AU 2003247826B2
Authority
AU
Australia
Prior art keywords
adp
polypeptide
protein
activity
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003247826A
Other languages
English (en)
Other versions
AU2003247826A1 (en
Inventor
Rita Bortell
Christelle Bourgeois
Joel Moss
Linda Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
United States Department of Health and Human Services
Original Assignee
University of Massachusetts Amherst
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst, United States Department of Health and Human Services filed Critical University of Massachusetts Amherst
Publication of AU2003247826A1 publication Critical patent/AU2003247826A1/en
Assigned to UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Assigned to THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF MASSACHUSETTS reassignment THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Request for Assignment Assignors: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER
Application granted granted Critical
Publication of AU2003247826B2 publication Critical patent/AU2003247826B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003247826A 2002-06-28 2003-06-27 Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins Ceased AU2003247826B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39303302P 2002-06-28 2002-06-28
US60/393,033 2002-06-28
PCT/US2003/020498 WO2004003195A1 (en) 2002-06-28 2003-06-27 Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins

Publications (2)

Publication Number Publication Date
AU2003247826A1 AU2003247826A1 (en) 2004-01-19
AU2003247826B2 true AU2003247826B2 (en) 2008-04-24

Family

ID=30000965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003247826A Ceased AU2003247826B2 (en) 2002-06-28 2003-06-27 Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins

Country Status (6)

Country Link
US (2) US7541139B2 (enExample)
EP (1) EP1549746A4 (enExample)
JP (1) JP2005531640A (enExample)
AU (1) AU2003247826B2 (enExample)
CA (1) CA2490290A1 (enExample)
WO (1) WO2004003195A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511015B2 (en) * 2002-02-19 2009-03-31 The United States Of America As Represented By The Department Of Health And Human Services Modified defensins and their use
WO2004003195A1 (en) * 2002-06-28 2004-01-08 The Government Of The United States Of America,As Represented By The Secretary Of The Department Of Health And Human Services Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins
EP1824506A2 (en) * 2004-12-08 2007-08-29 Novartis AG Use of organic compounds
US8828380B2 (en) 2009-09-10 2014-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the treatment of pulmonary disease and method of producing proteins of use therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965190A (en) * 1986-07-31 1990-10-23 Howard Hughes Medical Institute Methods for the identification of mutations in the human phenylalanine hydroxylase gene using DNA probes
US5716816A (en) * 1992-05-22 1998-02-10 The United States Of America As Represented By The Department Of Health And Human Services Clones encoding mammalian ADP-ribosylarginine hydrolases
EP0673440A4 (en) * 1992-11-30 1997-10-01 Us Health NAD: ARGININE ADP-RIBOSYL TRANSFERASE FROM THE MUSCLES OF MAMMALS.
US5386021A (en) * 1993-04-16 1995-01-31 The United States Of America, As Represented By The Department Of Health & Human Services Mammalian guanine nucleotide binding protein with an ADP-rybosylation factor domain
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US6015668A (en) 1994-09-30 2000-01-18 Life Technologies, Inc. Cloned DNA polymerases from thermotoga and mutants thereof
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
GB9918155D0 (en) 1999-08-02 1999-10-06 Zeneca Ltd Proteins and peptides
WO2004003195A1 (en) * 2002-06-28 2004-01-08 The Government Of The United States Of America,As Represented By The Secretary Of The Department Of Health And Human Services Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins

Also Published As

Publication number Publication date
US20090203878A1 (en) 2009-08-13
JP2005531640A (ja) 2005-10-20
US7541139B2 (en) 2009-06-02
US20060074037A1 (en) 2006-04-06
EP1549746A1 (en) 2005-07-06
US7923535B2 (en) 2011-04-12
WO2004003195A1 (en) 2004-01-08
AU2003247826A1 (en) 2004-01-19
CA2490290A1 (en) 2004-01-08
EP1549746A4 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
US8106006B2 (en) Modified defensins and their use
US11413332B2 (en) Methods of using interleukin-10 for treating diseases and disorders
AU2014254019B2 (en) Methods of using interleukin-10 for treating diseases and disorders
EP3209320B1 (en) Methods of using interleukin-10 for treating diseases and disorders
Rigby et al. Rat RT6. 2 and mouse Rt6 locus 1 are NAD+: arginine ADP ribosyltransferases with auto-ADP ribosylation activity
US7923535B2 (en) Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins
AU2013344973B2 (en) Compositions and methods for the treatment of ectodermal dysplasia
US20190307849A1 (en) Methods of using interleukin-10 for treating diseases and disorders
DK3202413T3 (en) MODIFIED PEPTIDES AND ITS APPLICATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP2527837A1 (en) Methods of inhibiting cell death or inflammation in a mammal
EP2032601B1 (en) Peptides regulating the surface expression of the t cell receptor
WO2001096574A1 (en) Novel enzyme gene and its expression product
RS51900B (sr) Deglikozilovani i desijalidovani dugi pentraksin ptx3
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
WO2001071038A1 (en) Inhibition of penicillin resistance in s. pneumoniae

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT TO THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES.

PC1 Assignment before grant (sect. 113)

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

Free format text: FORMER APPLICANT(S): THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARYOF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES; UNIVERSITY O F MASSACHUSETTS MEDICAL CENTER

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired